Peptide Science14 April 2026
An educational overview of how peptides are defined in biochemistry, what distinguishes them from proteins, hormones, and small molecules, and why these distinctions matter for research and regulatory classification.
Pathway Guides10 April 2026
Most peptides in Australia are classified as Schedule 4 (Prescription Only) under the Poisons Standard. Here's what that means for access and legality.
TGA Updates8 April 2026
A comprehensive look at the key peptide scheduling changes the TGA has implemented since mid-2025, including Melanotan II reclassification and compounding framework updates.
Pathway Guides5 April 2026
A step-by-step guide to legally accessing peptide therapies in Australia through prescription pathways, including costs and what to expect.
Market Intelligence28 March 2026
A detailed comparison of grey market peptide sources versus legitimate prescription access, covering quality, legality, cost, and health risks.
Global Regulatory20 March 2026
How the US FDA's Category 1 bulk drug substance list is affecting peptide availability and compounding supply chains in Australia.
Data Reports15 March 2026
Key data points from the Australian peptide market in Q1 2026, covering provider growth, prescribing trends, grey market activity, and enforcement actions.